These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 17993768)

  • 1. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.
    Naumnik B; Klejna K; Koc-Żórawska E; Myśliwiec M
    Adv Med Sci; 2013; 58(2):382-7. PubMed ID: 23959668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
    Siomou E; Challa A; Printza N; Giapros V; Petropoulou F; Mitsioni A; Papachristou F; Stefanidis CJ
    Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
    Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
    Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
    Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
    Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
    Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
    Dovio A; Data V; Carignola R; Calzolari G; Vitetta R; Ventura M; Saba L; Severino A; Angeli A
    J Rheumatol; 2008 Nov; 35(11):2206-13. PubMed ID: 18843778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
    Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
    Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
    Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers of vascular calcification in elderly hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Mol Cell Biochem; 2013 Feb; 374(1-2):21-7. PubMed ID: 23124853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
    J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.